- Home
- PRO vs ATAI Comparison
PRO vs ATAI Comparison
Compare PRO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRO
- ATAI
- Stock Information
- Founded
- PRO 1985
- ATAI 2018
- Country
- PRO United States
- ATAI Netherlands
- Employees
- PRO N/A
- ATAI N/A
- Industry
- PRO EDP Services
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- PRO Technology
- ATAI Health Care
- Exchange
- PRO Nasdaq
- ATAI Nasdaq
- Market Cap
- PRO 1.1B
- ATAI 1.1B
- IPO Year
- PRO 2007
- ATAI 2021
- Fundamental
- Price
- PRO $23.05
- ATAI $5.84
- Analyst Decision
- PRO Buy
- ATAI Strong Buy
- Analyst Count
- PRO 8
- ATAI 5
- Target Price
- PRO $26.46
- ATAI $14.00
- AVG Volume (30 Days)
- PRO 1.6M
- ATAI 7.0M
- Earning Date
- PRO 10-27-2025
- ATAI 11-14-2025
- Dividend Yield
- PRO N/A
- ATAI N/A
- EPS Growth
- PRO N/A
- ATAI N/A
- EPS
- PRO N/A
- ATAI N/A
- Revenue
- PRO $351,682,000.00
- ATAI $2,309,000.00
- Revenue This Year
- PRO $10.33
- ATAI $736.04
- Revenue Next Year
- PRO $10.76
- ATAI N/A
- P/E Ratio
- PRO N/A
- ATAI N/A
- Revenue Growth
- PRO 8.92
- ATAI 510.85
- 52 Week Low
- PRO $13.61
- ATAI $1.04
- 52 Week High
- PRO $29.84
- ATAI $6.75
- Technical
- Relative Strength Index (RSI)
- PRO 79.87
- ATAI 54.11
- Support Level
- PRO $22.99
- ATAI $5.50
- Resistance Level
- PRO $23.08
- ATAI $6.23
- Average True Range (ATR)
- PRO 0.05
- ATAI 0.47
- MACD
- PRO -0.24
- ATAI -0.05
- Stochastic Oscillator
- PRO 77.42
- ATAI 36.10
About PRO PROS Holdings Inc.
Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.